GEN Exclusives

More »

GEN News Highlights

More »
Jul 1, 2013

BMS, Pfizer Report Phase III Results for Acute Venous Thromboembolism Drug

  • Bristol-Myers Squibb and Pfizer this weekend presented results from their Phase III AMPLIFY trial evaluating Eliquis® (apixaban) as a single agent for the treatment of patients with acute venous thromboembolism (VTE), which includes symptomatic deep vein thrombosis (DVT) and/or pulmonary embolism (PE).

    Reporting in the New England Journal of Medicine and at the International Society on Thrombosis and Haemostasis Congress being held in Amsterdam, the companies showed that Eliquis demonstrated comparable efficacy to current standard of care in patients with DVT and/or PE, plus a 69% relative risk reduction for major bleeding compared with current standard of care.

    “These results complement the previously published results for the AMPLIFY-EXT study,” the University of Perugia’s Giancarlo Agnelli, M.D., professor of internal medicine and lead investigator of the study, explained in a statement. “Together these studies represent exciting data in the field of VTE treatment and indicate that apixaban may offer an important potential alternative in both acute and extended anticoagulation therapy for VTE patients.”

    BMS and Pfizer said that, based on the results of both AMPLIFY and AMPIFY-EXT, they plan to initiate regulatory filings for the initial long-term treatment of VTE, as well as for extended prevention of recurrent VTE.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »